1. Home
  2. DRD vs COAG Comparison

DRD vs COAG Comparison

Compare DRD & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DRDGOLD Limited

DRD

DRDGOLD Limited

SELL

Current Price

$22.93

Market Cap

2.1B

ML Signal

SELL

COAG

Hemab Therapeutics Holdings Inc. Common Stock

SELL

Current Price

$38.99

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DRD
COAG
Founded
1895
2020
Country
South Africa
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2002
2026

Fundamental Metrics

Financial Performance
Metric
DRD
COAG
Price
$22.93
$38.99
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $63.00
AVG Volume (30 Days)
226.0K
★ 476.4K
Earning Date
02-12-2027
11-10-2026
Dividend Yield
★ 4.46%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.33
N/A
Revenue Next Year
$18.47
N/A
P/E Ratio
$15.32
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.47
$27.38
52 Week High
$39.37
$55.42

Technical Indicators

Market Signals
Indicator
DRD
COAG
Relative Strength Index (RSI) 42.08 53.48
Support Level $22.76 $28.46
Resistance Level $26.57 $51.07
Average True Range (ATR) 0.77 3.72
MACD -0.11 -0.20
Stochastic Oscillator 13.41 37.45

Price Performance

Historical Comparison
DRD
COAG

About DRD DRDGOLD Limited

DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment, including exploration, extraction, processing, and smelting. Its reportable operating segments are: Ergo and FWGR. Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and FWGR is a surface gold retreatment operation that treats old slime dams in the West Rand goldfields. The Ergo segment derives the vast majority of the company's revenue.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: